A study on relationship between metabolic syndrome and colorectal cancer

To investigate the effects of metabolic syndrome (MS) and its components on the pathological manifestations and metastasis of colorectal cancer (CRC).

Clinical and pathological data of inpatients with CRC admitted to our hospital from January 1st 2010 to December 31st 2017 were collected, including the patients' general information, initial symptoms, previous history, family history, whether MS or related components were complicated, endoscopic description, imaging diagnosis, pathological diagnosis and metastasis. According to the diagnostic criteria of MS, the patients were divided into MS group and non-MS group, and then patients in non-MS group were further grouped based on whether they met MS single component. The clinical and pathological characteristics in each group were analyzed by SPSS 20.0 statistical software.

Among 1528 CRC patients, 76 (4.9%) were complicated with MS. CRC patients complicated with MS and those complicated with hypertension alone or diabetes alone were diagnosed at higher age, and most of them were elderly (p<0.05). CRC patients with body mass index (BMI) ≥25 kg/m2 were diagnosed at lower age (p<0.05). The infiltration depth of CRC patients with diabetes was higher than that in the non-diabetic group, and it was more likely to invade the whole layer (p<0.05). The locations of CRC lesions in different BMI subgroups, fatty liver and nonfatty liver subgroups had statistically significant differences (p<0.05). In BMI ≥25 kg/m2 group, CRC was mostly located in the left colon and rectum, while it was mostly located in the rectum in CRC patients with fatty liver.

Reducing the occurrence of MS and its components can reduce the incidence of CRC, and reduce its pathological manifestations and affect its metastasis at the same time.